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Una strategia efficace che testi i casi sospetti, tracci gli infetti e rintracci i loro contatti (Test, Track, 
Trace - TTT) è utile nel ridurre il dilagare della corrente pandemia di COVID-19, ma l’attuazione di 
uno screening sierologico di massa riguardante sia le IgM che le IgG (e eventualmente le IgA per 
valutare l’efficacia di diversi vaccini nell’elicitare l’immunità locale) rimane centrale per pianificare 
l’uscita dal lockdown in molti Paesi. 
I test sierologici di massa potrebbero limitare i test molecolari sui tamponi nei casi sospetti che hanno 
sviluppato anticorpi durante una precedente infezione asintomatica di COVID-19; soprattutto essi 
sono essenziali per identificare i soggetti sieronegativi che devono essere vaccinati. 
Il test progettato usa una nuova forma di fase solida per ELISA, una punta immunoadsorbente, e un 
nuovo metodo basato sulla doppia reazione eseguita utilizzando contemporaneamente due fasi solide: 
il micropozzetto standard che cattura le IgM (per poi rilevarne la specificità) impedendo interferenze 
con le IgG specifiche per il SARS-CoV-2, che vengono catturate dalla punta immersa nel medesimo 
micropozzetto. In questo modo si possono ottenere test sierologici per la ricerca simultanea di diversi 
isotipi anticorpali, limitando le reciproche interferenze. 
 
Abstract 
An effective strategy that tests suspected cases, tracks infected people and traces their contacts (TTT) 
will help reduce the spread of the current COVID-19 pandemic, but serological mass testing 
concerning both IgM and IgG (and IgA, in order to evaluate the local immunity stimulated by 
different vaccines) is central to lockdown exit plans in many countries.  
Serological mass testing can avoid swab analyses in suspected cases which developed antibodies 
during a previous asymptomatic and not diagnosed COVID-19 infection; above all, it is essential to 
individuate seronegative persons to vaccinate. 
The designed test uses a new shaped ELISA, the immunosorbent pin, and a new method based on the 
double reaction performed using simultaneously two different solid phases, able to separate, detect 
and differentiate immunoglobulin isotypes: the standard microwell (on which sample IgM are bound 
and tested about their specificity in the following steps; in this way IgM do not interfere with specific 
anti SARS-CV-2 IgG) and the pin, which binds specific anti SARS-CoV-2 IgG when immersed in 
the same microwell. The test has been conceived in order to run simultaneously different antibody 
detection tests and to avoid interferences generated by different antibody isotypes in serological tests. 
 
Introduction 
On 11 March 2020, the World Health Organization declared COVID-19 a pandemic [1]. "You cannot 
fight a fire blindfolded, and we cannot stop this pandemic if we don't know who is infected… Test, 
test, test", WHO Director-General Tedros Adhanom Ghebreyesus said on 16 March 2020.  
The adopted RT-PCR based tests detect the recently emerged SARS-CoV-2 in nasopharyngeal and 
oropharyngeal swabs: nevertheless, even though they have high sensitivity and specificity, kits and 
equipment necessary to run them are limited in some geographical areas; moreover, they do not give 
information about past infections. 
Serological tests are absolutely effective in estimating the real dimension of the COVID-19 
pandemic, including current, recent and past infections. 
Among them, rapid tests (lateral flow chromatographic immunoassay for the qualitative detection of 
IgG and IgM antibodies to SARS-CoV-2 in human fingerstick whole blood specimens) are useful in 
POCs, but they are unreliable to screen persons that need vaccination and those that do not, due to 
their sensitivity and specificity parameters. 
Enzyme linked immuno-sorbent assay (ELISA) based tests are among the most sensitive and specific 
immunoassays and they are overall adopted to detect antibodies; running different antibody tests 
worldwide, however, could slow down sanitary interventions.  
An effective strategy that tests suspected cases, tracks infected people and traces their contacts (TTT) 
will help reduce the spread of the current COVID-19 pandemic [2], but serological mass testing 
concerning both IgM, IgA and IgG is central to lockdown exit plans in many countries. They are 
absolutely effective in estimating the real dimension of the COVID-19 pandemic, including current, 
recent and past infections. 
 
The new ELISA design and the innovative immunoreaction involving different solid phases 
For the aforementioned, the development of a modular COVID-19 diagnostic kit - detecting IgM, 
IgA and IgG in blood serum or in saliva samples, even simultaneously, with the high sensitivity and 
specificity of the ELISA method - is of utmost importance in the course of the COVID-19 pandemic. 
The test design can be achieved resorting to: 
- the patent US7510687 [3], which describes the multi-immunosorbent device as an innovative 
shaped ELISA solid phase, consisting in a rod with multiple, protruding and immunosorbent 
ogival pins on which the immunocomplex is adsorbed, while in the meantime the microwells 
in which the pins are immersed act only as containers; the method has been successfully 
experimented in the frame of collaboration agreements with the EC - DG JRC concerning 
animal infectious diseases and food safety issues [4-7]; 
- the PCT/IB2012/052021 - WO 2012/143912, in which pins are immersed in oversized 
coated wells; different immunocomplexes are adsorbed on the pin surface and on the 
microwell surface [8]. 
Integrating both of the above said inventions, an innovative immunoreaction has been designed, 
involving immunosorbent solid phases having different formats: pins and microwells.  
Each solid phase specifically adsorbs one of the three immunoglobulins to detect, in order to avoid 
reciprocal interferences in the detection of the immunocomplexes involving the SARS-CoV-2. 
The proposed test design has been conceived as a modular tool, useful in the detection of a specific 
immunoglobulin isotype, up to the IgM, IgA and IgG simultaneous detection. 
The differently shaped solid phases adopted in the test are differently coated: 
- the microwell is coated with monoclonal antibody anti Human IgM (µ-chain specific) in 
order to bind sample IgM; 
- ogival pins are coated with capturing antibody binding the SARS-CoV-2 selected antigen, 
in order to bind specific IgA or IgG potentially present in the sample; 
some non-immunosorbent microwells serve as mere reagent containers (vessel), in which the coated 
pins are immersed. 
 
IgM and IgG simultaneous detection 
1. The sample is dispensed in the coated microwell containing a proper amount of diluting solution. 
1a. Monoclonal antibody anti Human IgM (µ-chain specific) coating the microwell binds 
the sample IgM during the incubation step, as in the ELISA method (figure 1a). 
 
 
1b. At the end of the previous incubation time, a pin coated with capturing antibody binding 
the SARS-CoV-2 selected antigen is immersed in the sample inside the microwell; the SARS-





2. At the end of the incubation:  
2a. the microwell is washed and filled with the HRP-conjugate SARS-CoV-2 antigen, which 
binds specific IgM adsorbed on the microwell surface (figure 2a); 
2b. the pin is lifted and washed; the HRP-conjugate monoclonal antibody anti Human IgG (g-
chain specific) is dispensed in a vessel (a non-immunosorbent microwell), then the pin is 




3. At the end of the incubation and the washing of the two immunosorbent solid phases: 
3a. the microwell is filled with the chromogenic substrate (3,3’,5,5’-tetramethylbenzidine - 
TMB) and the chromogenic reaction develops in it (figure 3a); 
3b. the pin is immersed in the vessel containing the chromogenic substrate (TMB), in which 
the chromogenic reaction develops (figure 3b). 
 
 
4. After incubation, the pin is lifted and thrown; the chromogenic reaction is stopped adding an acidic 
solution (sulphuric acid) both in the microwell and the vessel; the Absorbance / Optical Density (OD) 
is read in both of them through the ELISA-reader at l = 450/620 nm (figure 4). 
 
 
Time by time, microstrips can be chosen (or arranged in microplates) in order to detect one, two or 
three immunoglobulin isotypes: 
- by analysing one or two immunoglobulins isotypes, high through-put can be reached fitting 
mass screening purposes; 
- by analysing IgM, IgG and IgA elicited by different viral antigens, accurate tests can deeply 
indagate the immunological response during the COVID-19 infection and its correlation with 
symptoms and viral excretion. 
IgM and IgG simultaneous detection is performed diluting samples in the purple marked microwells, 
where IgM are detected and in which pins are immersed; IgG are then detected in the adjacent 
microwells (figure 5). 
 
In the designed test: 
- immobilizing IgM on the microwell surface, SARS-CoV-2 selected antigen adsorbed on the 
pin surface remains available to bind IgG even in case of low levels; therefore, IgG detection 
is scarcely affected by IgM; 
- preventing the IgM interference in binding the viral antigens, that could hinder the low IgG 
adsorption, more reliable results can be obtained and especially when a quantitative test runs 
in diluted samples; 
- since blood samples contain different IgG derived from past infections, the specific IgG are 
bound and adsorbed on the solid phases through the whole SARS-CoV-2 or its selected 
antigens; 
- IgM anti SARS-CoV-2 are detectable only in case of COVID-19 current infections, when 
they are the predominant IgM in the sample; consequently, most IgM bound through the 
monoclonal antibody anti Human IgM coating the microwell surface are potentially directed 
to the SARS-CoV-2 selected antigen and their specificity can be detected through the HRP-
conjugate anti SARS-CoV-2 selected antigen in the following steps;  
- in case the IgM high level could hinder the IgG detection, the positive IgM test highlights 
the positive cases anyway, also if the IgG detection tests give negative results due to the low 
level of IgG compared to the IgM level; 
- controls or calibrators have to be included in the test (the negative and the positive control 
sera etc.). 
 
IgM, IgA and IgG simultaneous detection 
1. The sample is dispensed (in triplicate) and incubated in three microwells containing a proper 
amount of diluting solution:  
- two microwells are coated with monoclonal antibody anti Human IgM; 
- one non-coated microwell is dedicated to the specificity control in absence of antigen. 
At the end of incubation: 
- two pins coated with capturing antibody binding the SARS-CoV-2 selected antigen, 
alternatively dedicated to the IgA detection and to the IgG detection, are immersed in the 
coated microwells; 
- the non-coated pin is immersed in the non-coated microwell. 
During this incubation step, specific IgA and IgG adsorb on the pins.  
In absence of non-specific binding, no adsorption occurs in the non-coated microwell and on the pin 
immersed in it. 
2. After the incubation and the washing of microwells and pins: 
- the pins are immersed in vessels (non-coated microwells) containing: 
- HRP-conjugate monoclonal antibody anti IgA (a-chain specific), which binds 
the specific IgA adsorbed on the pin surface; 
- HRP-conjugate monoclonal antibody anti IgG (g-chain specific), which binds 
the specific IgG adsorbed on the pin surface; 
- HRP-conjugate polyclonal antibodies anti Human immunoglobulins useful in 
the specificity control; 
- the HRP-conjugate SARS-CoV-2 antigen is dispensed in the microwells dedicated to the 
IgM detection and to the specificity control. 
3. After the incubation and the washing of all the microwells, vessels and pins, the chromogenic 
substrate is dispensed; then, pins are immersed in it. 
4. The pins are lifted and thrown, the chromogenic reaction is stopped adding acidic solution in all 
the microwells and vessels forming the ELISA microplate, then the OD is read through the ELISA 
reader at l = 450/620 nm. 
The ELISA-microplate can be arranged using 8-well microstrips: 
- microstrips in columns 1, 2, 7 and 8 are coated with monoclonal antibody anti IgM; 
samples are dispensed in triplicate in columns 1-3 and 7-9; 
- microstrips in columns from 3 up to 6 and from 9 up to 12 are non-coated; microwells in 
columns 4-6 and 10-12 act as mere containers (vessels). 
The three pins used to test each sample are previously immersed in columns 1-3 (from which they 
are moved in columns 4-6) and in columns 7-9 (form which they are moved in columns 10-12), 
where proper reagents are sequentially dispensed (figures 6 and 7). 
Each microplate row is dedicated to two samples. 
 
 
In the designed test aimed to accurate diagnosis: 
- since it is of utmost importance to identify persons having current infections, which 
potentially excrete the SARS-CoV-2, the IgM detection runs in duplicate in order to obtain 
the most reliable results; 
- the test includes, for each sample, two controls highlighting the false positive results / non-
specific immunoreactions concerning the three analysed immunoglobulin isotypes (IgM, IgA 
and IgG);  
- in case the IgM high level could hinder the IgG and the IgA detection, the positive IgM test 
highlights the positive cases anyway, also if the IgG and the IgA detection tests give negative 
results due to the low level of IgG or IgA compared to the IgM level; 
- the immuno-response can be evaluated considering two different SARS-CoV-2 antigens: an 
“a” selected antigen can be HRP-conjugated and a “b” selected antigen having a second 
epitope can be immobilized on the pin surface; in that way, IgM detection concerns antibodies 
directed to the “a” antigen and IgG detection concerns antibodies directed to the “b” antigen, 
in order to evaluate simultaneously up to 4 epidemiological parameters in the current infected 
persons: IgM, IgG, immuno-response to SARS-CoV-2 “a” antigen and to SARS-CoV-2 “b” 
antigen (potentially, antigens can be selected in order to detect virus mutations) (figure 8); a 
third antigen can be used in the IgA detection in order to have information concerning up to 
six epidemiological parameters; 
- the test can be arranged adsorbing the sample IgG on the microwell (replacing the IgM 
detection previously described) and the sample IgA on the pin or vice versa, in order to deeply 
investigate the IgA correlation with severe cases and to evaluate the local immunity stimulated 
by different vaccines; 
- other controls have to be included in the test (negative and positive control sera or calibrators, 
etc.); 







The two antigens can be selected among the main immunogenic SARS-CoV-2 proteins: the 
nucleoprotein (N) and - in the Spike glycoprotein trimer (S) - the S1 subunit, its N-terminal (S1A) 
domain and its receptor-binding domain (RBD) [9].  
S2 subunit is highly conserved and thus plays a role in the cross-reactivity of the whole S antigen. 
S1 is a specific antigen for SARS-CoV-2 diagnostics, since no cross-reaction has been observed in 
patients seropositive for endemic HCoVs (HCoV-HKU1, HCoV-OC43, HCoV-NL63, and HCoV-
229E) and MERS-CoV. The cross-reactivity resulting from the high degree of similarity between S1 
and RBD of SARS-CoV and SARS-CoV-2 does not produce false-positives results due to the fact 
that SARS-CoV has not circulated in the human population since 2003. 
N protein detects SARS-CoV-2 specific antibodies with high specificity and sensitivity. 
RBD and N protein ELISAs are more sensitive than S1 ELISA in detecting antibodies in mildly 
infected patients. 
Therefore, detecting antibodies against 2 different antigens might be needed to confirm the findings 
and avoid false-negative results in mass testing and surveillance studies [10]. 
Alternatively, the inactivated whole-virus can be used, in order to conduct a more comprehensive 
epidemiological survey.       
   
Engineering 
Since the protocol concerning the pins runs through UP and DOWN movements, the above described 
method could automatically run modifying and engineering the commercially available automated 
ELISA systems in order to add mechanisms able to grip and to move pins OUT and IN microwells 
and vessels filled at the moment by programmed dispensers. 
Moreover: 
- washing steps are easy to perform, thanks to the ogival shaped pins that can be squirted with 
washing solution and gently dried through air stream from the top, in order to allow the 
washing solution to flow away dragging the non-adsorbed antibodies or HRP-conjugates; 
- the test can use miniaturized pins and ELISA 384-well microplates, in order to occupy the 
reduced space available in a compact instrument, maintaining the high through-put required 
for laboratories and POCs; 
- pins can be used as single elements (figure 9) or they can be assembled as in the pin-device 
[5], in which one or more pins are dedicated to the sample analysis and one pin is dedicated 
to the negative control in absence of antigen, in order to evaluate the non-specific immuno-
reactions / false positive test results; 
- stop solution is unnecessary to stop the chromogenic reaction in the vessel, since it is stopped 





Collecting data could efficiently contribute to estimate, worldwide, the following epidemiological 
parameters: 
1. recent / current infections (if IgM detection occurs); 
2. past infections, also the asymptomatic ones (if IgG detection occurs);  
3. seroprevalence in large population; 
4. a more affordable Transmission Rate (R0) calculation; 
5. a more affordable Case Fatality Rate (CFR) calculation;  
6. correlation between IgA and IgG levels and case severity; 
7. persons that do not need vaccination (since they have developed their own immuno-response); 
8. vaccination durability concerning the humoral and the local immuno-response; 
9. protecting effects of vaccines due to the elicited neutralising antibodies. 
Moreover, the test could be adopted to individuate: 
- persons not required to comply with restriction measures imposed in the countries and 
regions put under lockdown; 
- persons who are already naturally immunized, which can resume productive, educational, 
artistic, commercial, professional, supporting and economic activities. These individuals will 
have to be identified until the launching of the vaccine campaign and monitored through 
repeated tests, in order to verify the permanence of antibodies over time and their correlation 
with the potential intermittent viral excretion, if serological and molecular tests are conducted.   
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